|
MINI-SYMPOSIUM AND PIPELINE UPDATE
London, UK, 23 November 2006 Proximagen Neuroscience plc (AIM: PRX), the drug discovery and development company focused on neurodegenerative diseases, is pleased to announce that it is holding its second annual mini-symposium on Neurodegenerative Disease and giving a pipeline update today. The mini-symposium will take place at the Company's offices near London Bridge from 4.45pm to 7pm.
Short presentations will be given by the following speakers: Kenneth Mulvany, Chief Executive, Proximagen; Professor Niall Quinn, National Hospital for Neurology and Neurosurgery, London; Dr Ray Chaudhuri, King's College Hospital, London; Tom Isaacs, Founder of "Movers and Shakers"; Professor Peter Jenner, Chief Scientific Officer, Proximagen; Ray Hill, Executive Director and Head, Licensing and External Research, Europe, Merck, Sharp and Dohme and Dr Bruce Campbell, Chairman, Proximagen.
Commenting on the mini-symposium and Proximagen's pipeline, Kenneth Mulvany, Chief Executive Officer of Proximagen, said:
"We are delighted to be hosting the second annual mini-symposium on neurodegenerative diseases with such a prestigious line-up of guest speakers. The event aims to provide an insight into the impact on patients of diseases such as Parkinson's and Alzheimer's and to highlight the potential of Proximagen's in-house R&D pipeline which is focused on developing new and more effective therapies for these patients.
Proximagen has made measured progress across each of its programmes since last year's symposium and we have generated some exciting data.
Work on our lead programme, PRX1, for improving the symptomatic treatment of Parkinson's disease, has identified four compounds that exhibit exciting characteristics when compared to current treatments. We look forward to updating shareholders on our research findings."
Ends
For more information, or an invitation to today's meeting, please contact:
For more information please contact:
Proximagen Neuroscience plc (www.proximagen.com)
020 7848 6938 Kenneth Mulvany, Chief Executive Officer
James Hunter, Financial Director
Buchanan Communications
020 7466 5000
Tim Anderson / Mary-Jane Johnson / Catherine Breen
About Proximagen
Proximagen is a drug discovery and development company that is primarily focused on the identification and subsequent out-licensing of novel therapeutics to improve the quality of life for patients suffering from neurodegenerative disease such as Parkinson's disease and Alzheimer's disease.
Proximagen is building a development pipeline to address the significant medical needs of these patients and has made substantial progress in four proprietary programmes. Proximagen anticipates out-licensing its programmes following successful Phase II proof of concept studies and commercialising carefully selected in-licensed and collaborative programmes.
The Company also generates significant revenues from providing assessment and advisory services to major pharmaceutical companies on their drug candidates for these therapeutic areas.
Proximagen joined the AIM market of the London Stock Exchange in March 2005.
For more information please visit the Company's web site: www.proximagen.com.
| 
